



7-10 day  
TAT\*


ALL SOLID TUMORS

# OmniSeq<sup>®</sup> INSIGHT

Make confident treatment decisions  
based on the entire tumor profile



We deliver both DNA and RNA fusion sequencing results for 96% of sequenced cases, reflecting our commitment to quality control and robust workflow.



FFPE tissue

- Resection specimens
- Needle core biopsies
- Cell blocks from FNA

# OmniSeq<sup>®</sup> INSIGHT

## Pan-solid tumor profiling

Analyzing a single tumor biopsy with advanced DNA and RNA next-generation sequencing (NGS) technology, OmniSeq INSIGHT can identify treatment options in **one comprehensive, easy-to-read report**.

Available for order and result delivery through a portal and electronic interface.

### Identify approved drug candidates

#### Comprehensive genomics

- Identifies genomic alterations in 523 genes
- Fusions/splice variants using RNA-Seq hybrid capture
- Coverage of clinical practice guideline-recommended biomarkers across solid tumor types
- HRD\*\* status available when clinically indicated

### Immunotherapy eligibility

#### Comprehensive immune profiling

- PD-L1 IHC
- MSI and TMB profiling

### Eligible clinical trials

List of patient-eligible clinical trials within 200 miles of patient's physical address<sup>1</sup>

- Testing for biomarkers with clinical trial associations

### The result report includes:

- A summary page of marker findings, including pertinent negatives
- Therapy considerations section with treatment setting, approval status and multi-marker associations
- Flags potential cancer-associated hereditary variants
- Additionally, available as a dynamic online report

OmniSeq <sup>®</sup> INSIGHT		PATIENT Jane Doe	TUMOR TYPE Ovarian Serous Adenocarcinoma	REPORT DATE 2025	ORDER ID	labcorp   Oncology																																																																																																						
<table border="1"> <tr> <th colspan="2">PATIENT</th> </tr> <tr> <td colspan="2">DIAGNOSIS C56.9, Malignant neoplasm of unspecified ovary; Metastatic</td> </tr> <tr> <td colspan="2">NAME Jane Doe</td> </tr> <tr> <td>DOB</td> <td>SEX Female</td> </tr> <tr> <td>MRN</td> <td></td> </tr> <tr> <td>ORDER ID P-</td> <td></td> </tr> <tr> <td>REPORT DATE</td> <td>2025</td> </tr> <tr> <th colspan="2">SPECIMEN</th> </tr> <tr> <td colspan="2">FACILITY My Medical Center Lab</td> </tr> <tr> <td>ID</td> <td></td> </tr> <tr> <td>SOURCE</td> <td>Peritoneal Biopsy</td> </tr> <tr> <td>COLLECTION DATE</td> <td></td> </tr> <tr> <td>RECEIVED DATE</td> <td></td> </tr> <tr> <th colspan="2">CLIENT</th> </tr> <tr> <td>ORDERING PROVIDER</td> <td></td> </tr> <tr> <td>ORDERING PROVIDER NPI</td> <td></td> </tr> <tr> <td>PROVIDER FACILITY</td> <td></td> </tr> <tr> <td>ORDERING FACILITY</td> <td></td> </tr> <tr> <td colspan="2">OmniSeq Clinical Support For questions or to discuss results: 1-800-781-1259 MedOncSupport@labcorp.com</td> </tr> <tr> <td colspan="2">OmniSeq<sup>®</sup> INSIGHT interrogates 523 genes by next generation sequencing for mutations, select copy number alterations, HLA Class I genotypes and fusions/splice variants, microsatellite instability, homologous recombination deficiency (HRD) status when clinically indicated, tumor mutational burden (TMB), and PD-L1 by immunohistochemistry (IHC).</td> </tr> <tr> <td colspan="2">See last page of report for all tested markers</td> </tr> <tr> <td colspan="2"> <table border="1"> <tr> <th colspan="2">MARKER FINDINGS</th> <th>See MARKER DETAILS for additional information</th> </tr> <tr> <td rowspan="4">Genomic Variants (Positive)</td> <td>SHV /Indel</td> <td>JAK1 N11fs NF1 c.4578-43_4586del TP53 Y220C</td> </tr> <tr> <td>Fusion</td> <td>No positive findings</td> </tr> <tr> <td>Copy Gain</td> <td>No positive findings</td> </tr> <tr> <td>Copy Loss</td> <td>No positive findings</td> </tr> <tr> <td colspan="3">See APPENDIX for variants of unknown significance (VUS)</td> </tr> <tr> <td rowspan="4">Signatures</td> <td colspan="2">Tumor Mutational Burden (TMB): 5.5 mut/Mb (Not High)</td> </tr> <tr> <td colspan="2">Microsatellite Instability (MSI): MS-Stable</td> </tr> <tr> <td colspan="2">Homologous Recombination Deficiency (HRD) Status: Positive</td> </tr> <tr> <td colspan="2">Genomic Instability Score (GIS): 69 (Positive)</td> </tr> <tr> <td rowspan="4">Immune Markers</td> <td colspan="2">BRCA1/2 Mutation Status: Negative</td> </tr> <tr> <td colspan="2">PD-L1 IHC (22C3): Tumor Proportion Score &lt;1%</td> </tr> <tr> <td colspan="2">HLA Class I: A*01:01, 03:01 B*07:02, 15:24 C*03:03, 07:02</td> </tr> <tr> <td colspan="2">Note: PD-L1 is measured by immunohistochemistry (IHC) and RNA-expression profiling, and HLA Class I genotyping using next generation sequencing. See APPENDIX for additional details.</td> </tr> <tr> <td colspan="3"> <table border="1"> <tr> <th colspan="2">PERTINENT NEGATIVE GENOMIC VARIANTS</th> <th>FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected</th> </tr> <tr> <td>BRCA1 VUS0E</td> <td>BRCA2 VUS0E</td> <td>HER2 (ERBB2) gain</td> </tr> <tr> <td>BRCA1 loss</td> <td>BRCA2 loss</td> <td>KRAS mut</td> </tr> <tr> <td>BRCA1 mut</td> <td>BRCA2 mut</td> <td>NTRK1/2/3 fusion</td> </tr> <tr> <td>BRCA2 loss</td> <td>BRCA2 mut</td> <td>RET fusion</td> </tr> </table> </td> </tr> <tr> <td colspan="2"> <table border="1"> <tr> <th>COMMENTS</th> </tr> <tr> <td>Pathologist No pathologist comments.</td> </tr> <tr> <td>Testing All testing was completed.</td> </tr> <tr> <td>Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.</td> </tr> <tr> <td>NF1 c.4578-43_4586del</td> </tr> </table> </td> </tr> </table></td></tr></table>							PATIENT		DIAGNOSIS C56.9, Malignant neoplasm of unspecified ovary; Metastatic		NAME Jane Doe		DOB	SEX Female	MRN		ORDER ID P-		REPORT DATE	2025	SPECIMEN		FACILITY My Medical Center Lab		ID		SOURCE	Peritoneal Biopsy	COLLECTION DATE		RECEIVED DATE		CLIENT		ORDERING PROVIDER		ORDERING PROVIDER NPI		PROVIDER FACILITY		ORDERING FACILITY		OmniSeq Clinical Support For questions or to discuss results: 1-800-781-1259 MedOncSupport@labcorp.com		OmniSeq <sup>®</sup> INSIGHT interrogates 523 genes by next generation sequencing for mutations, select copy number alterations, HLA Class I genotypes and fusions/splice variants, microsatellite instability, homologous recombination deficiency (HRD) status when clinically indicated, tumor mutational burden (TMB), and PD-L1 by immunohistochemistry (IHC).		See last page of report for all tested markers		<table border="1"> <tr> <th colspan="2">MARKER FINDINGS</th> <th>See MARKER DETAILS for additional information</th> </tr> <tr> <td rowspan="4">Genomic Variants (Positive)</td> <td>SHV /Indel</td> <td>JAK1 N11fs NF1 c.4578-43_4586del TP53 Y220C</td> </tr> <tr> <td>Fusion</td> <td>No positive findings</td> </tr> <tr> <td>Copy Gain</td> <td>No positive findings</td> </tr> <tr> <td>Copy Loss</td> <td>No positive findings</td> </tr> <tr> <td colspan="3">See APPENDIX for variants of unknown significance (VUS)</td> </tr> <tr> <td rowspan="4">Signatures</td> <td colspan="2">Tumor Mutational Burden (TMB): 5.5 mut/Mb (Not High)</td> </tr> <tr> <td colspan="2">Microsatellite Instability (MSI): MS-Stable</td> </tr> <tr> <td colspan="2">Homologous Recombination Deficiency (HRD) Status: Positive</td> </tr> <tr> <td colspan="2">Genomic Instability Score (GIS): 69 (Positive)</td> </tr> <tr> <td rowspan="4">Immune Markers</td> <td colspan="2">BRCA1/2 Mutation Status: Negative</td> </tr> <tr> <td colspan="2">PD-L1 IHC (22C3): Tumor Proportion Score &lt;1%</td> </tr> <tr> <td colspan="2">HLA Class I: A*01:01, 03:01 B*07:02, 15:24 C*03:03, 07:02</td> </tr> <tr> <td colspan="2">Note: PD-L1 is measured by immunohistochemistry (IHC) and RNA-expression profiling, and HLA Class I genotyping using next generation sequencing. See APPENDIX for additional details.</td> </tr> <tr> <td colspan="3"> <table border="1"> <tr> <th colspan="2">PERTINENT NEGATIVE GENOMIC VARIANTS</th> <th>FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected</th> </tr> <tr> <td>BRCA1 VUS0E</td> <td>BRCA2 VUS0E</td> <td>HER2 (ERBB2) gain</td> </tr> <tr> <td>BRCA1 loss</td> <td>BRCA2 loss</td> <td>KRAS mut</td> </tr> <tr> <td>BRCA1 mut</td> <td>BRCA2 mut</td> <td>NTRK1/2/3 fusion</td> </tr> <tr> <td>BRCA2 loss</td> <td>BRCA2 mut</td> <td>RET fusion</td> </tr> </table> </td> </tr> <tr> <td colspan="2"> <table border="1"> <tr> <th>COMMENTS</th> </tr> <tr> <td>Pathologist No pathologist comments.</td> </tr> <tr> <td>Testing All testing was completed.</td> </tr> <tr> <td>Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.</td> </tr> <tr> <td>NF1 c.4578-43_4586del</td> </tr> </table> </td> </tr> </table>		MARKER FINDINGS		See MARKER DETAILS for additional information	Genomic Variants (Positive)	SHV /Indel	JAK1 N11fs NF1 c.4578-43_4586del TP53 Y220C	Fusion	No positive findings	Copy Gain	No positive findings	Copy Loss	No positive findings	See APPENDIX for variants of unknown significance (VUS)			Signatures	Tumor Mutational Burden (TMB): 5.5 mut/Mb (Not High)		Microsatellite Instability (MSI): MS-Stable		Homologous Recombination Deficiency (HRD) Status: Positive		Genomic Instability Score (GIS): 69 (Positive)		Immune Markers	BRCA1/2 Mutation Status: Negative		PD-L1 IHC (22C3): Tumor Proportion Score <1%		HLA Class I: A*01:01, 03:01 B*07:02, 15:24 C*03:03, 07:02		Note: PD-L1 is measured by immunohistochemistry (IHC) and RNA-expression profiling, and HLA Class I genotyping using next generation sequencing. See APPENDIX for additional details.		<table border="1"> <tr> <th colspan="2">PERTINENT NEGATIVE GENOMIC VARIANTS</th> <th>FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected</th> </tr> <tr> <td>BRCA1 VUS0E</td> <td>BRCA2 VUS0E</td> <td>HER2 (ERBB2) gain</td> </tr> <tr> <td>BRCA1 loss</td> <td>BRCA2 loss</td> <td>KRAS mut</td> </tr> <tr> <td>BRCA1 mut</td> <td>BRCA2 mut</td> <td>NTRK1/2/3 fusion</td> </tr> <tr> <td>BRCA2 loss</td> <td>BRCA2 mut</td> <td>RET fusion</td> </tr> </table>			PERTINENT NEGATIVE GENOMIC VARIANTS		FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected	BRCA1 VUS0E	BRCA2 VUS0E	HER2 (ERBB2) gain	BRCA1 loss	BRCA2 loss	KRAS mut	BRCA1 mut	BRCA2 mut	NTRK1/2/3 fusion	BRCA2 loss	BRCA2 mut	RET fusion	<table border="1"> <tr> <th>COMMENTS</th> </tr> <tr> <td>Pathologist No pathologist comments.</td> </tr> <tr> <td>Testing All testing was completed.</td> </tr> <tr> <td>Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.</td> </tr> <tr> <td>NF1 c.4578-43_4586del</td> </tr> </table>		COMMENTS	Pathologist No pathologist comments.	Testing All testing was completed.	Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.	NF1 c.4578-43_4586del
PATIENT																																																																																																												
DIAGNOSIS C56.9, Malignant neoplasm of unspecified ovary; Metastatic																																																																																																												
NAME Jane Doe																																																																																																												
DOB	SEX Female																																																																																																											
MRN																																																																																																												
ORDER ID P-																																																																																																												
REPORT DATE	2025																																																																																																											
SPECIMEN																																																																																																												
FACILITY My Medical Center Lab																																																																																																												
ID																																																																																																												
SOURCE	Peritoneal Biopsy																																																																																																											
COLLECTION DATE																																																																																																												
RECEIVED DATE																																																																																																												
CLIENT																																																																																																												
ORDERING PROVIDER																																																																																																												
ORDERING PROVIDER NPI																																																																																																												
PROVIDER FACILITY																																																																																																												
ORDERING FACILITY																																																																																																												
OmniSeq Clinical Support For questions or to discuss results: 1-800-781-1259 MedOncSupport@labcorp.com																																																																																																												
OmniSeq <sup>®</sup> INSIGHT interrogates 523 genes by next generation sequencing for mutations, select copy number alterations, HLA Class I genotypes and fusions/splice variants, microsatellite instability, homologous recombination deficiency (HRD) status when clinically indicated, tumor mutational burden (TMB), and PD-L1 by immunohistochemistry (IHC).																																																																																																												
See last page of report for all tested markers																																																																																																												
<table border="1"> <tr> <th colspan="2">MARKER FINDINGS</th> <th>See MARKER DETAILS for additional information</th> </tr> <tr> <td rowspan="4">Genomic Variants (Positive)</td> <td>SHV /Indel</td> <td>JAK1 N11fs NF1 c.4578-43_4586del TP53 Y220C</td> </tr> <tr> <td>Fusion</td> <td>No positive findings</td> </tr> <tr> <td>Copy Gain</td> <td>No positive findings</td> </tr> <tr> <td>Copy Loss</td> <td>No positive findings</td> </tr> <tr> <td colspan="3">See APPENDIX for variants of unknown significance (VUS)</td> </tr> <tr> <td rowspan="4">Signatures</td> <td colspan="2">Tumor Mutational Burden (TMB): 5.5 mut/Mb (Not High)</td> </tr> <tr> <td colspan="2">Microsatellite Instability (MSI): MS-Stable</td> </tr> <tr> <td colspan="2">Homologous Recombination Deficiency (HRD) Status: Positive</td> </tr> <tr> <td colspan="2">Genomic Instability Score (GIS): 69 (Positive)</td> </tr> <tr> <td rowspan="4">Immune Markers</td> <td colspan="2">BRCA1/2 Mutation Status: Negative</td> </tr> <tr> <td colspan="2">PD-L1 IHC (22C3): Tumor Proportion Score &lt;1%</td> </tr> <tr> <td colspan="2">HLA Class I: A*01:01, 03:01 B*07:02, 15:24 C*03:03, 07:02</td> </tr> <tr> <td colspan="2">Note: PD-L1 is measured by immunohistochemistry (IHC) and RNA-expression profiling, and HLA Class I genotyping using next generation sequencing. See APPENDIX for additional details.</td> </tr> <tr> <td colspan="3"> <table border="1"> <tr> <th colspan="2">PERTINENT NEGATIVE GENOMIC VARIANTS</th> <th>FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected</th> </tr> <tr> <td>BRCA1 VUS0E</td> <td>BRCA2 VUS0E</td> <td>HER2 (ERBB2) gain</td> </tr> <tr> <td>BRCA1 loss</td> <td>BRCA2 loss</td> <td>KRAS mut</td> </tr> <tr> <td>BRCA1 mut</td> <td>BRCA2 mut</td> <td>NTRK1/2/3 fusion</td> </tr> <tr> <td>BRCA2 loss</td> <td>BRCA2 mut</td> <td>RET fusion</td> </tr> </table> </td> </tr> <tr> <td colspan="2"> <table border="1"> <tr> <th>COMMENTS</th> </tr> <tr> <td>Pathologist No pathologist comments.</td> </tr> <tr> <td>Testing All testing was completed.</td> </tr> <tr> <td>Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.</td> </tr> <tr> <td>NF1 c.4578-43_4586del</td> </tr> </table> </td> </tr> </table>		MARKER FINDINGS		See MARKER DETAILS for additional information	Genomic Variants (Positive)	SHV /Indel	JAK1 N11fs NF1 c.4578-43_4586del TP53 Y220C	Fusion	No positive findings	Copy Gain	No positive findings	Copy Loss	No positive findings	See APPENDIX for variants of unknown significance (VUS)			Signatures	Tumor Mutational Burden (TMB): 5.5 mut/Mb (Not High)		Microsatellite Instability (MSI): MS-Stable		Homologous Recombination Deficiency (HRD) Status: Positive		Genomic Instability Score (GIS): 69 (Positive)		Immune Markers	BRCA1/2 Mutation Status: Negative		PD-L1 IHC (22C3): Tumor Proportion Score <1%		HLA Class I: A*01:01, 03:01 B*07:02, 15:24 C*03:03, 07:02		Note: PD-L1 is measured by immunohistochemistry (IHC) and RNA-expression profiling, and HLA Class I genotyping using next generation sequencing. See APPENDIX for additional details.		<table border="1"> <tr> <th colspan="2">PERTINENT NEGATIVE GENOMIC VARIANTS</th> <th>FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected</th> </tr> <tr> <td>BRCA1 VUS0E</td> <td>BRCA2 VUS0E</td> <td>HER2 (ERBB2) gain</td> </tr> <tr> <td>BRCA1 loss</td> <td>BRCA2 loss</td> <td>KRAS mut</td> </tr> <tr> <td>BRCA1 mut</td> <td>BRCA2 mut</td> <td>NTRK1/2/3 fusion</td> </tr> <tr> <td>BRCA2 loss</td> <td>BRCA2 mut</td> <td>RET fusion</td> </tr> </table>			PERTINENT NEGATIVE GENOMIC VARIANTS		FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected	BRCA1 VUS0E	BRCA2 VUS0E	HER2 (ERBB2) gain	BRCA1 loss	BRCA2 loss	KRAS mut	BRCA1 mut	BRCA2 mut	NTRK1/2/3 fusion	BRCA2 loss	BRCA2 mut	RET fusion	<table border="1"> <tr> <th>COMMENTS</th> </tr> <tr> <td>Pathologist No pathologist comments.</td> </tr> <tr> <td>Testing All testing was completed.</td> </tr> <tr> <td>Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.</td> </tr> <tr> <td>NF1 c.4578-43_4586del</td> </tr> </table>		COMMENTS	Pathologist No pathologist comments.	Testing All testing was completed.	Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.	NF1 c.4578-43_4586del																																																	
MARKER FINDINGS		See MARKER DETAILS for additional information																																																																																																										
Genomic Variants (Positive)	SHV /Indel	JAK1 N11fs NF1 c.4578-43_4586del TP53 Y220C																																																																																																										
	Fusion	No positive findings																																																																																																										
	Copy Gain	No positive findings																																																																																																										
	Copy Loss	No positive findings																																																																																																										
See APPENDIX for variants of unknown significance (VUS)																																																																																																												
Signatures	Tumor Mutational Burden (TMB): 5.5 mut/Mb (Not High)																																																																																																											
	Microsatellite Instability (MSI): MS-Stable																																																																																																											
	Homologous Recombination Deficiency (HRD) Status: Positive																																																																																																											
	Genomic Instability Score (GIS): 69 (Positive)																																																																																																											
Immune Markers	BRCA1/2 Mutation Status: Negative																																																																																																											
	PD-L1 IHC (22C3): Tumor Proportion Score <1%																																																																																																											
	HLA Class I: A*01:01, 03:01 B*07:02, 15:24 C*03:03, 07:02																																																																																																											
	Note: PD-L1 is measured by immunohistochemistry (IHC) and RNA-expression profiling, and HLA Class I genotyping using next generation sequencing. See APPENDIX for additional details.																																																																																																											
<table border="1"> <tr> <th colspan="2">PERTINENT NEGATIVE GENOMIC VARIANTS</th> <th>FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected</th> </tr> <tr> <td>BRCA1 VUS0E</td> <td>BRCA2 VUS0E</td> <td>HER2 (ERBB2) gain</td> </tr> <tr> <td>BRCA1 loss</td> <td>BRCA2 loss</td> <td>KRAS mut</td> </tr> <tr> <td>BRCA1 mut</td> <td>BRCA2 mut</td> <td>NTRK1/2/3 fusion</td> </tr> <tr> <td>BRCA2 loss</td> <td>BRCA2 mut</td> <td>RET fusion</td> </tr> </table>			PERTINENT NEGATIVE GENOMIC VARIANTS		FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected	BRCA1 VUS0E	BRCA2 VUS0E	HER2 (ERBB2) gain	BRCA1 loss	BRCA2 loss	KRAS mut	BRCA1 mut	BRCA2 mut	NTRK1/2/3 fusion	BRCA2 loss	BRCA2 mut	RET fusion																																																																																											
PERTINENT NEGATIVE GENOMIC VARIANTS		FDA or NCCN guideline indicated variants for this tumor type listed but NOT detected																																																																																																										
BRCA1 VUS0E	BRCA2 VUS0E	HER2 (ERBB2) gain																																																																																																										
BRCA1 loss	BRCA2 loss	KRAS mut																																																																																																										
BRCA1 mut	BRCA2 mut	NTRK1/2/3 fusion																																																																																																										
BRCA2 loss	BRCA2 mut	RET fusion																																																																																																										
<table border="1"> <tr> <th>COMMENTS</th> </tr> <tr> <td>Pathologist No pathologist comments.</td> </tr> <tr> <td>Testing All testing was completed.</td> </tr> <tr> <td>Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.</td> </tr> <tr> <td>NF1 c.4578-43_4586del</td> </tr> </table>		COMMENTS	Pathologist No pathologist comments.	Testing All testing was completed.	Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.	NF1 c.4578-43_4586del																																																																																																						
COMMENTS																																																																																																												
Pathologist No pathologist comments.																																																																																																												
Testing All testing was completed.																																																																																																												
Potential Germline Variants Listed alterations may represent inherited variants and should prompt dedicated germline testing and/or genetic counseling in the appropriate clinical context. More information on germline testing can be found at <a href="http://www.invitae.com">www.invitae.com</a> or at 800-436-3037.																																																																																																												
NF1 c.4578-43_4586del																																																																																																												

OmniSeq INSIGHT is performed at OmniSeq, Inc., 700 Ellcott Street, Buffalo NY 14203 | 1 (800) 781-1259 | CLIA ID: 33D2098748 | CAP #9405346. Signed by Eric Severson at RS-001, Shakti Ramkissoon, MD, Medical Director 03/27/24 3:33 PM EDT. This document contains confidential health information protected by state and federal laws. If you received this document in error, please contact OMS-PrivacyOfficer@labcorp.com

## A consolidated assay for two different treatment paradigms:



### Genomic profiling

- 523-gene NGS panel
- HRD\*\*
- DNA and RNA sequencing
- SNVs, indels, CNAs and fusions
- Interrogation of full coding regions
- HLA genotyping



### Immune profiling

- PD-L1 IHC
- TMB
- MSI

## Why choose OmniSeq INSIGHT:


- Genes aligned with FDA approvals, professional practice guidelines and clinical trials
- HRD\*\* including GIS and HRR-related genes for PARP inhibitor therapeutic selection in patients with ovarian cancer and other solid tumors
- Full coding region coverage for each gene, which improves variant detection compared to “hotspot” testing strategies
- An RNA-seq hybrid capture approach that allows for the detection of common and novel fusions
- Targeting of unique emerging and actionable markers
- HLA genotyping to identify HLA Class I alleles at HLA-A, HLA-B and HLA-C genes

## When to consider OmniSeq INSIGHT:


- For patients with advanced and recurrent cancer when evidence-based guidelines recommend broad genomic profiling for evaluation of alterations to guide targeted therapy
- When considering clinical trials as an option for treatment and a patient’s unique genomic and/or immune profile facilitates enrollment
- When a cancer lacks an effective standard-of-care therapy or when a tumor is poorly differentiated and of uncertain origin to help identify potential treatments
- When relapse or disease progression has occurred after prior therapies
- Use of HLA genotype as a biomarker for patient inclusion in immunotherapeutic clinical trials requires MHC Class I status

OmniSeq INSIGHT delivers the distinct advantage of leveraging three NGS technologies, leading to the highest quality results:<sup>2</sup>

- DNA sequencing to detect SNVs, indels, CNAs, TMB, HRD\*\*, and MSI
- RNA sequencing by hybrid-capture to detect known and unknown fusion partners



Identifies both known and unknown fusion partners



This approach fails to identify unknown fusion partners

## Sample requirements (include pathology report)

Formalin-fixed paraffin embedded (FFPE) tissue

- Resection specimens
- Needle core biopsies
- Cell blocks from fine needle aspirates (FNAs)

**\*\*Do not submit decalcified specimens, cytology smears or samples from hematologic malignancies**

FFPE block (preferred) or 15 unbaked, positively charged, unstained slides cut at 5 µm plus one H&E.

## Proven expertise in FFPE sample processing

A proprietary pre-analytical FFPE extraction process maximizes our ability to yield DNA and RNA sequencing data from limited specimens.



### Labcorp's high laboratory quality standards

- NYS CLEP approved
- ISO 13485:2016 and ISO 15189:2022
- CLIA and CAP accredited



### Labcorp's broad national coverage

- In-network with most major health plans
- 1,600 contractual relationships with plans, payers and other healthcare organizations

## Powering better decisions

When you need trusted information to make clear, better health decisions, consider us your source for oncology testing. Whether you are advancing therapies through clinical trials or diagnosing and treating individuals with cancer, we know you are working relentlessly to improve patient outcomes. We can help.

### Result reporting

Turnaround time of 7-10 calendar days

### Extensive managed care contracts

Help patients maximize their benefits.

### Genetic counseling

A national network of genetic counselors to help inform and support your patients. Call us at 855-GC-CALLS or 855-422-2557.

### OmniSeq clinical support

For questions or to discuss results:  
1-800-781-1259  
MedOncSupport@labcorp.com

### Visit us

[oncology.labcorp.com](http://oncology.labcorp.com)

\*Turnaround time is reported based on the number of days from sample receipt in the lab to release of clinical report

\*\* Homologous Recombination Deficiency (HRD) result is only available for patients with ovarian, fallopian tube and primary peritoneal cancers

#### Abbreviations

CNAs: Copy number alterations  
FFPE: Formalin-fixed paraffin embedded  
FNA: Fine-needle aspiration  
HLA: Human leukocyte antigen  
HRD: Homologous recombination deficiency  
HRR: Homologous recombination repair  
IHC: Immunohistochemistry  
Indels: Insertions/deletions  
MHC: Major histocompatibility complex  
MSI: Microsatellite instability  
PARP: Poly-ADP ribose polymerase  
SNVs: Single-nucleotide variants  
TMB: Tumor mutational burden

#### References

1. OmniSeq Knowledgebase - trial radius may be modified for select locations.
2. Conroy JM, et. al., A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. *PLoS One*. 2021;16(12):e0260089. doi:10.1371/journal.pone.0260089

For more information about OmniSeq INSIGHT visit [oncology.labcorp.com/omniseq](http://oncology.labcorp.com/omniseq), or contact your Labcorp Oncology sales representative.

